Mesothelioma Life Expectancy and Survival Rates: What the Research Shows

Understanding Mesothelioma Survival Statistics

When people first encounter mesothelioma survival statistics, the numbers can be alarming. The American Cancer Society reports an overall five-year relative survival rate of approximately 12% for pleural mesothelioma — meaning that about 12 of every 100 patients diagnosed are alive five years later.^[1] However, these figures reflect historical data that predate the most recent advances in immunotherapy and surgical technique, and they represent averages across all patients — not the experience of any individual.

Survival statistics are most useful as a starting point for understanding prognosis, but they cannot predict what will happen in a specific case. Age at diagnosis, mesothelioma type and cell type, stage at diagnosis, overall health, and access to specialized treatment all affect individual outcomes. As Mayo Clinic Press notes, no two mesothelioma cases are the same, and some patients significantly exceed median survival expectations.^[8]

Survival Rates by Stage

Mesothelioma is staged using the TNM system (Tumor, Node, Metastasis), with Stage I representing localized disease and Stage IV indicating widespread metastasis. Early-stage diagnosis correlates strongly with better outcomes, though mesothelioma is diagnosed at an early stage in only a minority of patients due to its extended latency period and nonspecific early symptoms.

For peritoneal mesothelioma, the prognosis has improved substantially over the past two decades due to the introduction of cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). Published research has documented median survival exceeding 50 months in surgical candidates with peritoneal disease — a dramatic improvement over the roughly 12 months historically associated with chemotherapy alone.^[3]

How Cell Type Affects Prognosis

Mesothelioma cell type is one of the strongest independent predictors of survival. Three primary cell types are identified:^[2]

• Epithelioid (most common, ~60% of cases): The best-prognosis cell type; these cells tend to grow more slowly and respond better to treatment. Patients with epithelioid tumors generally have the longest median survival.
• Sarcomatoid (~10–20% of cases): The most aggressive cell type; associated with the shortest survival times and the poorest response to standard treatments.
• Biphasic (~30% of cases): Contains both epithelioid and sarcomatoid components; prognosis falls between the two, depending on the proportion of each cell type.

PMC research confirms that epithelioid histology, younger age (particularly under 45), female sex, and earlier stage are the four most consistent positive prognostic factors across mesothelioma studies.^[2]

How Treatment Affects Life Expectancy

Treatment significantly impacts mesothelioma survival. The four main treatment modalities are surgery, chemotherapy, radiation therapy, and immunotherapy. For many patients, combination approaches — particularly surgery followed by chemotherapy — produce better outcomes than any single modality alone.

Chemotherapy

The landmark clinical trial establishing pemetrexed (Alimta) plus cisplatin as first-line treatment showed median overall survival of 12.1 months compared to 9.3 months for cisplatin alone — leading to the first FDA approval for a mesothelioma-specific treatment in February 2004.^[6][7]

Immunotherapy — The 2020 Breakthrough

On October 2, 2020, the FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for unresectable malignant pleural mesothelioma — the first new mesothelioma drug approval in 16 years. The pivotal CheckMate-743 trial demonstrated median overall survival of 18.1 months with immunotherapy versus 14.1 months with standard chemotherapy.^[4][5]

Surgery

Eligible patients with early-stage pleural mesothelioma may be considered for surgery — either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). For peritoneal mesothelioma, CRS + HIPEC has been particularly impactful. Mayo Clinic notes that surgery is most appropriate for fit patients with early-stage, epithelioid tumors.^[9]

Emerging Treatments and Clinical Trials

The field of mesothelioma research is advancing rapidly. NCI maintains an active database of mesothelioma clinical trials, covering novel immunotherapy combinations, CAR T-cell therapy, gene therapy, and targeted agents.^[11]

Notably, NCI's Center for Cancer Research is conducting a Phase I CAR T-cell trial specifically for mesothelioma, targeting the mesothelin protein that is overexpressed on mesothelioma cells. Clinical care at the NIH Clinical Center in Bethesda, Maryland is provided at no cost to trial participants — a significant consideration for patients seeking cutting-edge treatments.^[10]

Patients interested in clinical trial eligibility can search ClinicalTrials.gov or ask their oncologist to evaluate their eligibility. Clinical trial participation often provides access to emerging therapies before they receive broad FDA approval, and in some cases may significantly extend survival.

Frequently Asked Questions